oleclumab plus osimertinib for advanced egfrm nsclc
Published 3 years ago • 267 plays • Length 2:53Download video MP4
Download video MP3
Similar videos
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
4:56
active trial update: egfrm nsclc
-
3:54
teslisotuzumab vedotin and osimertinib for egfr-mutant, c-met-overexpressing nsclc
-
3:34
flaura2: egfrm dynamics in nsclc treated with osimertinib
-
1:35
afatinib for advanced egfrm-positive nsclc
-
3:02
osimertinib for treating non-small cell lung cancer
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
4:38
new agents for egfr nsclc: osimertinib and beyond
-
0:55
osimertinib for egfr-mutant lung cancer
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
6:06
osimertinib, the standard for egfr nsclc
-
11:53
insight 2: a phase ii study of tepotinib plus osimertinib in met-amplified nsclc
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam